Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Grows By 94.6%

Akari Therapeutics, Plc (NASDAQ:AKTX) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 144,200 shares, an increase of 94.6% from the December 31st total of 74,100 shares. Based on an average daily trading volume, of 55,400 shares, the short-interest ratio is presently 2.6 days. Approximately 1.2% of the company’s shares are sold short.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Akari Therapeutics in a research note on Tuesday, January 21st. They set a “sell” rating for the company.

Akari Therapeutics Trading Up 3.1 %

Shares of NASDAQ AKTX opened at $1.33 on Wednesday. The stock has a 50 day moving average of $1.17 and a 200-day moving average of $2.44. Akari Therapeutics has a 12 month low of $0.90 and a 12 month high of $4.40.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.